| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Ultan F. Power | Q46776575 |
| P2093 | author name string | Ultan F Power | |
| P433 | issue | 1 | |
| P304 | page(s) | 38-44 | |
| P577 | publication date | 2008-01-01 | |
| P1433 | published in | Journal of Clinical Virology | Q15759726 |
| P1476 | title | Respiratory syncytial virus (RSV) vaccines--two steps back for one leap forward | |
| P478 | volume | 41 |
| Q36776952 | A nonviral pHEMA+chitosan nanosphere-mediated high-efficiency gene delivery system |
| Q36005114 | Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains |
| Q34457791 | Assembly and immunological properties of Newcastle disease virus-like particles containing the respiratory syncytial virus F and G proteins |
| Q36256989 | Cotton rat immune responses to virus-like particles containing the pre-fusion form of respiratory syncytial virus fusion protein. |
| Q35077892 | Decrease in formalin-inactivated respiratory syncytial virus (FI-RSV) enhanced disease with RSV G glycoprotein peptide immunization in BALB/c mice |
| Q39398265 | Direct whole-genome deep-sequencing of human respiratory syncytial virus A and B from Vietnamese children identifies distinct patterns of inter- and intra-host evolution |
| Q34170117 | Infection-enhancing lipopeptides do not improve intranasal immunization of cotton rats with a delta-G candidate live-attenuated human respiratory syncytial virus vaccine |
| Q36937656 | Intranasal immunization with a helper-dependent adenoviral vector expressing the codon-optimized fusion glycoprotein of human respiratory syncytial virus elicits protective immunity in BALB/c mice |
| Q40076730 | Intranasal immunization with a single dose of the fusion protein formulated with a combination adjuvant induces long-term protective immunity against respiratory syncytial virus |
| Q36363325 | Long-term and memory immune responses in mice against Newcastle disease virus-like particles containing respiratory syncytial virus glycoprotein ectodomains |
| Q34059404 | Modification of the respiratory syncytial virus f protein in virus-like particles impacts generation of B cell memory |
| Q35745343 | Murine immune responses to virus-like particle-associated pre- and postfusion forms of the respiratory syncytial virus F protein |
| Q34990420 | Nanoparticle vaccines encompassing the respiratory syncytial virus (RSV) G protein CX3C chemokine motif induce robust immunity protecting from challenge and disease |
| Q37086092 | Neonatal immunization with respiratory syncytial virus glycoprotein fragment induces protective immunity in the presence of maternal antibodies in mice |
| Q39780308 | Newcastle disease virus-like particles as a platform for the development of vaccines for human and agricultural pathogens |
| Q37841269 | Prevention of serious respiratory syncytial virus-related illness. I: Disease pathogenesis and early attempts at prevention |
| Q37232803 | Primary high-dose murine norovirus 1 infection fails to protect from secondary challenge with homologous virus |
| Q36994716 | RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. |
| Q37412509 | Recent advances in diagnosis, prevention, and treatment of human respiratory syncytial virus. |
| Q33840252 | Reduced Dicer expression in the cord blood of infants admitted with severe respiratory syncytial virus disease |
| Q36030806 | Relative impact of influenza and respiratory syncytial virus in young children |
| Q56833872 | Report of the 2nd “French Clinical Vaccinology Meeting Jean-Gerard Guillet”: Immunization and respiratory diseases |
| Q37822453 | Respiratory syncytial virus disease: update on treatment and prevention |
| Q45145012 | Respiratory syncytial virus infection in children with severe motor and intellectual disabilities |
| Q34566553 | Respiratory syncytial virus represses glucocorticoid receptor-mediated gene activation |
| Q35761061 | Respiratory syncytial virus, an ongoing medical dilemma: an expert commentary on respiratory syncytial virus prophylactic and therapeutic pharmaceuticals currently in clinical trials |
| Q30529666 | Respiratory viruses from hospitalized children with severe pneumonia in the Philippines. |
| Q38696909 | The Central Conserved Region (CCR) of Respiratory Syncytial Virus (RSV) G Protein Modulates Host miRNA Expression and Alters the Cellular Response to Infection |
| Q41926470 | The NS1 protein of Respiratory syncytial virus blocks glucocorticoid receptor nuclear translocation by targeting IPO13 may account for glucocorticoid insensitive |
| Q40163890 | The importance of RSV F protein conformation in VLPs in stimulation of neutralizing antibody titers in mice previously infected with RSV. |
| Q34222406 | The respiratory syncytial virus G protein conserved domain induces a persistent and protective antibody response in rodents |
| Q34603346 | Therapeutic targeting of respiratory syncytial virus G-protein. |
| Q33558356 | Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice |
Search more.